• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

My 11-Year Metastatic Breast Cancer Story Defied the Standard Path

by MM360 Staff | Apr 21, 2025 | Uncategorized

Source: CureToday articles Diagnosed in 2014, I share my unique aggressive treatment journey over 11 years, highlighting a common hope for more time and better treatments. Read More

Trodelvy Plus Keytruda May Slow Progression in mTNBC

by MM360 Staff | Apr 21, 2025 | Uncategorized

Source: CureToday articles In some patients with advanced triple-negative breast cancer, Trodelvy plus Keytruda was associated with an improvement in disease progression. Read More

Pausing BTKi for Vaccine Did Not Boost Immunity in CLL

by MM360 Staff | Apr 21, 2025 | Uncategorized

Source: CureToday articles Pausing treatment during vaccination did not improve immunity in patients with chronic lymphocytic leukemia and should not be recommended, a trial found. Read More

“Chillin’ Out” and Finding Our Cancer Community

by MM360 Staff | Apr 20, 2025 | Uncategorized

Source: CureToday articles After nearly 30 years with cancer — community, research and education have helped us find hope, strength and purpose in the face of chronic blood cancers. Read More

Bavencio Maintains Bladder Cancer Benefit in Patients with Diabetes

by MM360 Staff | Apr 20, 2025 | Uncategorized

Source: CureToday articles Bavencio improved survival in patients with bladder cancer, irrespective of diabetes status, according to an analysis of the JAVELIN Bladder 100 trial. Read More

Optimal Jakafi Dosing Associated With Improved Outcomes in Myelofibrosis

by MM360 Staff | Apr 19, 2025 | Uncategorized

Source: CureToday articles Optimal dosing of Jakafi was associated with improved efficacy and manageable safety in patients with myelofibrosis, according to the ROMEI clinical trial. Read More
« Older Entries
Next Entries »

Recent Content

  • Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma
  • The impact of high-risk cytogenetics on treatment efficacy and outcomes of patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis of randomized controlled trials
  • FDA Approves Linvoseltamab-Gcpt for Treatment of Relapsed or Refractory Multiple Myeloma
  • FDA Grants Accelerated Approval to Lynozyfic for Multiple Myeloma
  • FDA accelerates linvoseltamab-gcpt approval for multiple myeloma
  • Comprehensive machine learning analysis of PANoptosis signatures in multiple myeloma identifies prognostic and immunotherapy biomarkers
  • The impact of high-risk cytogenetics on treatment efficacy and outcomes of patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis of randomized controlled trials
  • Spatial and single cell mapping of castleman disease reveals key stromal cell types and cytokine pathways
  • Managing IEC-associated enterocolitis following CAR-T therapy in multiple myeloma
  • What Should Patients with Multiple Myeloma Know After ASCO 2025?
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT